MigraKet: Energy for the brain
Safety, tolerability and efficacy of exogenous ketone bodies for preventive treatment of migraine (MigraKet): A randomised, placebo-controlled, double-blind study.
Approx. one billion people are suffering from migraine worldwide and yet, therapeutic options are still very limited. Research suggests that changes in energy metabolism could be part of migraine pathophysiology. Ketone bodies (KB) are endogenous alternative energy substrates. Our clinical trial assesses the efficacy and safety of KB supplements in 60-90 adult migraineurs (5-14 migraine days / months) at the University Hospital Basel. The total duration of the trial is approx. 6 months, consisting of 4 weeks baseline, 12 weeks intervention with KB powder or matched placebo and 8 weeks follow-up. The primary endpoint is the change in migraine days at the end of intervention compared to baseline. Additionally, changes in gene expression, fat-, protein- and glucose metabolism, inflammatory markers and quality of life will be examined.
We are currently recruiting.